Jennifer Craig
Family · Lansdale, PANPI 1093050759
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 240 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,683 and has fallen 69.6% since, to $512 in 2025. Among family clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 240 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$922
- GSK$448
- Novo Nordisk$401
- Lilly USA, LLC$309
- Pfizer$287
- Merck$257
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,18298%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 61 | $922 |
| GSK | 25 | $448 |
| Novo Nordisk | 22 | $401 |
| Lilly USA, LLC | 17 | $309 |
| Pfizer | 16 | $287 |
| Merck | 17 | $257 |
| AstraZeneca | 11 | $206 |
| Exact Sciences | 7 | $170 |
| Amgen | 9 | $167 |
| Bayer | 8 | $151 |
| Daiichi Sankyo Inc. | 6 | $123 |
| Astellas Pharma US Inc | 1 | $100 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $57 |
| Boehringer Ingelheim | 3 | $53 |
| Amarin Pharma, Inc. | 3 | $45 |
| Seqirus USA Inc | 3 | $44 |
| Harmony Biosciences LLC | 1 | $44 |
| Ironshore Pharmaceuticals Inc. | 2 | $43 |
| Kowa Pharmaceuticals America, Inc. | 3 | $40 |
| Johnson & Johnson | 2 | $38 |
| Corium, LLC | 2 | $36 |
| Alkermes, Inc. | 2 | $36 |
| Currax Pharmaceuticals LLC | 2 | $36 |
| Sanofi Pasteur Inc. | 1 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $26 |
| VBI Vaccine (delaware) Inc. | 1 | $23 |
| Vertos Medical, Inc. | 1 | $22 |
| Impel Pharmaceuticals Inc. | 1 | $18 |
| Novartis | 1 | $17 |
| Bausch Health US, LLC | 1 | $17 |
| Almatica Pharma LLC | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $15 |
How this compares
$4,282 in reported general payments places this provider in the 90th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $15,707 |
| JardianceEmpagliflozin | 11 | $14,713 |
| MounjaroTirzepatide | 11 | $14,339 |
| EliquisApixaban | 14 | $11,124 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,261 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 40 | $1,020 |
| Metoprolol Succinate | 24 | $773 |
| Atorvastatin Calcium | 69 | $669 |
| Rosuvastatin Calcium | 19 | $556 |
| Levothyroxine Sodium | 50 | $536 |
| Simvastatin | 28 | $403 |
| Doxycycline Hyclate | 40 | $384 |
| Losartan Potassium | 33 | $277 |
| Escitalopram Oxalate | 21 | $259 |
| Metformin Hcl | 17 | $251 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $448 | $19,96930 claims |
| Boehringer IngelheimJardiance | $53 | $14,71311 claims |
| Lilly USA, LLCMounjaro | $309 | $14,33911 claims |
| PfizerEliquis | $287 | $11,12414 claims |
| Almatica Pharma LLCSertraline Hcl | $17 | $13424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,717 family providers in Pennsylvania.
Other family in Lansdale
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
- Patricia HabdasPittsburgh$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.